Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash & Equivalents (2016 - 2025)

Arrowhead Pharmaceuticals' Cash & Equivalents history spans 16 years, with the latest figure at $201.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 274.18% year-over-year to $201.6 million; the TTM value through Dec 2025 reached $201.6 million, up 274.18%, while the annual FY2025 figure was $226.5 million, 120.62% up from the prior year.
  • Cash & Equivalents reached $201.6 million in Q4 2025 per ARWR's latest filing, down from $226.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $372.4 million in Q1 2021 to a low of $53.9 million in Q4 2024.
  • Average Cash & Equivalents over 5 years is $154.0 million, with a median of $129.8 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 18011.11% in 2021, then crashed 76.8% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $184.4 million in 2021, then grew by 9.66% to $202.2 million in 2022, then plummeted by 71.22% to $58.2 million in 2023, then fell by 7.43% to $53.9 million in 2024, then soared by 274.18% to $201.6 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Cash & Equivalents are $201.6 million (Q4 2025), $226.5 million (Q3 2025), and $129.8 million (Q2 2025).